MET is a potential target for use in combination therapy with EGFR inhibition in triple‐negative/basal‐like breast cancer

Kim, Yu Jin ; Choi, Jong‐Sun ; Seo, Jinwon ; Song, Ji‐Young ; Eun Lee, Seung ; Kwon, Mi Jung ; Kwon, Mi Jeong ; Kundu, Juthika ; Jung, Kyungsoo ; Oh, Ensel ; Shin, Young Kee ; Choi, Yoon‐La

International journal of cancer, 2014-05, Vol.134 (10), p.2424-2436 [Periódico revisado por pares]

Hoboken, NJ: Wiley-Blackwell

Texto completo disponível